Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Torben Noerup Nielsen who wrote (24966)	8/28/1998 12:49:00 AM
From: Tommy D	Read Replies (1) \| Respond to of 32384

You were questioning whether LGND was oversold. Maybe it is but I think what has been happening is all about the over all market, given the nature of LGND's current business. LGND has no earnings, is burning a reasonable amount of cash and offers great (IMHO) potential. Unfortunately, in a market where you are starting to have companies trading under book value, companies with great potential are not going to be treated very well. My take on preservation of capital, as I still like LGND(and I might be wrong about little share value will be recognized for potential) is to sell the stock and buy the warrants. I have both but in my mind, I limit the risk even if I pay a premium to get in. With the time remaining, its almost like buying a 2 year leap. Good luck to all and I hope people can post the good and the bad without P***ing on each other. The last short while has been enjoyable to read. I will now go back to lurking as I normally do. TommyD

To: Torben Noerup Nielsen who wrote (24966)	8/28/1998 4:54:00 AM
From: jayhawk969	Respond to of 32384

TNN, From Friday's NYT F.D.A. Approves Retinitis Treatment, a Gene Blocker The Food and Drug Administration has approved the first drug that works by blocking the action of a gene. Isis Pharmaceuticals Inc., a biotechnology company in Carlsbad, Calif., said it had received approval late Wednesday for its drug, fomivirsen, for the treatment of CMV retinitis, a virus that can cause blindness in AIDS patients. Fomivirsen will be made by Isis and marketed as Vitravene by Ciba Vision Corp., the eye-care unit of Novartis AG, the Swiss pharmaceutical giant. Shares of Isis rose 56.25 cents Thursday, to $9.8125, in Nasdaq trading. .............. The size of the market for Vitravene is not clear because the incidence of CMV retinitis has been in decline as AIDS patients live longer, healthier lives thanks to antiviral drugs. But recent studies show many patients either resisting or not tolerating those drugs, so infections like CMV retinitis may increase. Some analysts expect the market to be less than $20 million.......... Sounds like Karposi's. Is this an indication of what we can expect of Ontak's approval? The success of Vitravene "is one more piece in a mosaic of evidence that antisense can be used to make drugs," said Stanley Crook, the chairman and chief executive of Isis. "By itself, it is not enough to make me say that antisense will be the revolution I believed it would be, but it is an important piece. The evidence is overwhelming that antisense can work."..........